Program
EVER001
A development code.
Its studies are mostly in Glomerulonephritis, Membranous · Nephrosis, Lipoid, led by Everest Medicines (China).
Furthest: phase 2, since May 5, 20262 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Everest Medicines (China) | 21 open or running | phase 2since May 5, 2026 | Mar 9, 2023 | Dec 31, 2028phase 2 · NCT07614477 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2023First study: phase 1 study in Primary Membranous NephropathyFirst studyNCT05800873 · 31 enrolled · China
- May 5, 2026Phase 2 study in Nephrosis, LipoidPhase 2 reachedNCT07614477 · 45 planned · China
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Nephrosis, LipoidNCT07614477
TargetBeta
BTK →read by rule
“EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.”study text, by rule · the study
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07614477Nephrosis, Lipoid · China | 2 | Recruiting | Dec 31, 2028 | 45 |
| NCT05800873Primary Membranous Nephropathy · China | 1 | Completed | Jul 27, 2026 | 31 |
How it is read
Names in the registry
- “EVER001”, 3 entries
Codes read as this program: EVER001.
Conditions, from the studies’ own filings
- Glomerulonephritis, Membranous, 1 study
- Nephrosis, Lipoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.